NEOS Investment Management LLC Has $64.06 Million Stake in Gilead Sciences, Inc. $GILD

NEOS Investment Management LLC lifted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 59.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 577,119 shares of the biopharmaceutical company’s stock after buying an additional 215,619 shares during the period. NEOS Investment Management LLC’s holdings in Gilead Sciences were worth $64,060,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. GSA Capital Partners LLP bought a new stake in shares of Gilead Sciences during the 3rd quarter valued at $337,000. Rothschild Investment LLC increased its position in shares of Gilead Sciences by 18.5% in the third quarter. Rothschild Investment LLC now owns 5,380 shares of the biopharmaceutical company’s stock worth $597,000 after purchasing an additional 841 shares during the period. Beta Wealth Group Inc. raised its stake in Gilead Sciences by 5.1% in the third quarter. Beta Wealth Group Inc. now owns 6,218 shares of the biopharmaceutical company’s stock valued at $690,000 after purchasing an additional 302 shares in the last quarter. Merit Financial Group LLC lifted its position in Gilead Sciences by 0.3% during the third quarter. Merit Financial Group LLC now owns 48,072 shares of the biopharmaceutical company’s stock worth $5,336,000 after purchasing an additional 121 shares during the period. Finally, Glenview Trust Co grew its stake in Gilead Sciences by 2.1% during the third quarter. Glenview Trust Co now owns 187,726 shares of the biopharmaceutical company’s stock worth $20,838,000 after buying an additional 3,868 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Up 2.1%

Shares of GILD opened at $154.98 on Tuesday. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.68. Gilead Sciences, Inc. has a 52 week low of $93.37 and a 52 week high of $157.29. The stock has a market capitalization of $192.28 billion, a price-to-earnings ratio of 22.89, a PEG ratio of 2.06 and a beta of 0.36. The stock has a fifty day moving average of $130.94 and a 200-day moving average of $122.68.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. The business had revenue of $7.93 billion during the quarter, compared to analysts’ expectations of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The business’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.90 EPS. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, sell-side analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 30th. Investors of record on Friday, March 13th will be given a dividend of $0.82 per share. The ex-dividend date is Friday, March 13th. This represents a $3.28 annualized dividend and a yield of 2.1%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. Gilead Sciences’s dividend payout ratio is 46.68%.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Wolfe Research boosted their target price on shares of Gilead Sciences from $155.00 to $170.00 and gave the company an “outperform” rating in a research report on Thursday, February 12th. Leerink Partners boosted their price objective on shares of Gilead Sciences from $146.00 to $148.00 and gave the company an “outperform” rating in a research report on Wednesday, February 11th. Argus upped their target price on Gilead Sciences from $130.00 to $135.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Wall Street Zen lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, January 23rd. Finally, Deutsche Bank Aktiengesellschaft boosted their price target on Gilead Sciences from $135.00 to $155.00 and gave the stock a “buy” rating in a report on Wednesday, February 11th. Twenty-three analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $152.50.

Insider Buying and Selling at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 115,640 shares of the firm’s stock in a transaction on Thursday, February 5th. The shares were sold at an average price of $150.00, for a total transaction of $17,346,000.00. Following the completion of the transaction, the chief executive officer owned 613,912 shares of the company’s stock, valued at approximately $92,086,800. This trade represents a 15.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $124.31, for a total transaction of $372,930.00. Following the completion of the sale, the chief financial officer directly owned 150,503 shares in the company, valued at approximately $18,709,027.93. This represents a 1.95% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 288,891 shares of company stock valued at $40,303,946. 0.27% of the stock is owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.